Learn more Servier has signed an agreement to acquire Edgewise Therapeutics’ muscular dystrophy business in a deal valued at ...

Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has entered into ...

A trio of deals from Eli Lilly, Servier, and Avenzo highlights continued industry investment in rare diseases and oncology, ...

The Duchenne muscular dystrophy clinical trial analysis report delivers important insights into ongoing research of 75+ ...

New treatments and gene-based therapies are changing the outlook for those living with Duchenne Muscular Dystrophy, a rare genetic condition that causes muscles to weaken over time, allowing them to ...

The emergence of gene therapies and next-generation treatment is extending life expectancy into the thirties and beyond for people with Duchenne muscular dystrophy (DMD), shifting the focus from short ...

ITF Pharma has reached a commercial arrangement that will make its therapy for Duchenne muscular dystrophy, Duvyzat, an option for more than 500 NHS patients in England. Final draft guidance from ...

Edgewise Therapeutics will now focus on a handful of cardiovascular programs including EDG-7500 for hypertrophic cardiomyopathy thanks to the non-dilutive capital from France’s Servier. Servier is ...

Adults with MD in the U.S. report widespread gaps in sexual and reproductive healthcare, according to surveys and interviews ...

Hundreds of children living with spinal muscular atrophy (SMA) are set to benefit from two life-changing treatments, which have now received official approval for routine use across the NHS.

In addition to the upfront fee, Servier has committed up to $1.1 billion in regulatory and commercial milestones to acquire ...